Patient preference and satisfaction in erectile dysfunction therapy: a comparison of the three phosphodiesterase-5 inhibitors sildenafil, vardenafil and tadalafil

References

• NIH Consensus ConferenceImpotence. NIH Consensus Development Panel on ImpotenceJAMA1993270183908510302
   PubMed Web of Science ®Google Scholar
• FeldmanHAGoldsteinIHatzichristouDGKraneRJMcKinlayJBImpotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging StudyJ Urol1994151154618254833
   PubMed Web of Science ®Google Scholar
• WagnerGFugl-MeyerKSFugl-MeyerARImpact of erectile dysfunction on quality of life: patient and partner perspectivesInt J Impot Res20004S14446
   Google Scholar
• Sanchez-CruzJJCabrera-LeonAMartin-MoralesAFernandezABurgosRRejasJMale erectile dysfunction and health-related quality of lifeEur Urol20034424525312875945
   PubMed Web of Science ®Google Scholar
• Fugl-MeyerARLodnertGBranholmIBFugl-MeyerKSOn life satisfaction in male erectile dysfunctionInt J Impot Res199791411489315491
   PubMed Web of Science ®Google Scholar
• FisherWARosenRCEardlyISandMGoldsteinISexual experience of female partners of men with erectile dysfunctionJ Sex Med20052567568416422826
   PubMed Web of Science ®Google Scholar
• PonholzerATemmlCObermayrRWehrbergerCMadersbacherSIs erectile dysfunction an indicator for increased risk of coronary heart disease and stroke? 1Eur Urol200548351251815998563
   PubMed Web of Science ®Google Scholar
• BrigantiASaloniaAGallinaADrug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunctionNat Clin Pract Urol2005223924716474835
   PubMedGoogle Scholar
• LueTFA patient’s goal directed approach to erectile dysfunction and Peyronie’s diseaseCan J Urol19952S1317
   Google Scholar
• MontagueDKJarowJPBroderickGADmochowskiRRHeatonJPLueTFChapter 1: The management of erectile dysfunction: an AUA updateJ Urol2005174123023915947645
   PubMed Web of Science ®Google Scholar
• HatzimouratidisKHatzichristouDGA comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?Drugs200565121621165016060698
   PubMed Web of Science ®Google Scholar
• LueTFErectile dysfunctionN Engl J Med20003421802181310853004
   PubMed Web of Science ®Google Scholar
• RosenRCKostisJBOverview of phosphodiesterase 5 inhibitors in erectile dysfunction [abstract]Am J Cardiol200392918M
   PubMed Web of Science ®Google Scholar
• StrobergPHedelinHLjunggrenCPrescribing all phosphodiesterase 5 inhibitors to a patient with erectile dysfunction – a realistic and feasible option in everyday clinical practice – outcomes of a simple treatment regimeEur Urol20064990090716564126
   PubMed Web of Science ®Google Scholar
• WrightPJComparison of phosphodiesterase type 5 (PDE5) inhibitorsInt J Clin Pract200660896797516780568
   PubMed Web of Science ®Google Scholar
• GresserUGleiterCHComparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafilEur J Med Res2002743544612435622
   PubMed Web of Science ®Google Scholar
• PorstH2006Oral pharmacotherapy of erectile dysfunctionStandard practice in sexual medicine1st edBlackwell Publishing20068386
   Google Scholar
• SommerFEngelmannUFuture options for combination therapy in the management of erectile dysfunction in older menDrugs Aging20042155556415260511
   PubMed Web of Science ®Google Scholar
• McCulloughARBaradaJHFawzyAAchieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunctionUrology2002602 Suppl 2283812414331
   PubMed Web of Science ®Google Scholar
• McMahonCHigh dose sildenafil citrate as a salvage therapy for erectile dysfunction [abstract]Int J Impotence Res200214 Suppl 3S89Abstr, P5.11.
   Google Scholar
• McMahonCEfficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafilJ Sex Med2004129230016422959
   PubMed Web of Science ®Google Scholar
• PorstHSalvagetherapie mit taglicher dosierung von sildenafil bei non-respondern auf on-demand therapie mit 100 mg sildenafilUrologe A200342101330133614569381
   PubMedGoogle Scholar
• CartledgeJEardleyJorchardCImpairment of corpus cavernosal smooth muscle relaxation by glycosylated haemoglobin [abstract]Eur Urol199935 Suppl 2100Abstr. 399.
   Google Scholar
• SaltzmanEAGuayATJacobsonJImprovement in erectile function in men with organic erectile dysfunction by correction of elevated cholesterol levels: a clinical observationJ Urol200417225525815201788
   PubMed Web of Science ®Google Scholar
• MoralesABuvatJGoorenLJEndocrine aspects of sexual dysfunction in menJ Sex Med20041698116422986
   PubMed Web of Science ®Google Scholar
• DeBuskRDroryYGoldsteinIManagement of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton consensus panelAmJ Cardiol200086217518110913479
   PubMed Web of Science ®Google Scholar
• JackosnGMartinEMcGingESuccessful withdrawal oral long-acting nitrates to facilitate PDE5 inhibitor use in stable coronary disease patients with erectile dysfunctionJ Sex Med2005251351616422846
   PubMed Web of Science ®Google Scholar
• Viagra (sildenafil citrate) Prescribing Information. Accessed March 2008. Available from http://www.pfizer.com/files/products/uspi_viagra.pdf
   Google Scholar
• Levitra (vardenafil HCl). Prescribing information. Accessed March 2008. Available from http://www.univgraph.com/bayer/inserts/levitra.pdf
   Google Scholar
• Cialis (tadalafil). Prescribing information. Accessed March 2008. Available from http://pi.lilly.com/us/cialis-pi.pdf
   Google Scholar
• KlonerRAJacksonGEmmickJTInteraction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive menJ Urol20041721935194015540759
   PubMed Web of Science ®Google Scholar
• HedelinHStrobergPTreatments for erectile dysfunction based on patient-reported outcomesDrugs2005652245225116266193
   PubMed Web of Science ®Google Scholar
• Von KeitzARajferJSegalSA multicenter, randomized, double-blind, crossover study to evaluate patient preference for tadalafil and sildenafilEur Urol20044549950715041116
   PubMed Web of Science ®Google Scholar
• StrobergPMurphyACostiganTSwitching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preferenceClin Ther2003252724273714693300
   PubMed Web of Science ®Google Scholar
• McMahonCMKozlowskiRKKaufmanAKPotential predictors for treatment preference in men with erectile dysfunction taking sildenafil and tadalafil in an open-label switch trial [abstract]J Sex Med20041 Suppl 14016422982
   PubMed Web of Science ®Google Scholar
• EardleyIMironeVMontorsiFAn open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapyBJU Int2005961323133216287454
   PubMed Web of Science ®Google Scholar
• ClaesHIMVan PoppelHThe use of sildenafil, tadalafil and vardenafil in clinical practice [abstract]J Sex Med20041 Suppl 142
   Google Scholar
• MulhallJPMcLaughlinTPHarnettJPScottBBurhaniSRussellDMedication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunctionJ Sex Med2005284885516422809
   PubMed Web of Science ®Google Scholar
• KellPHvidstenKMorantSFactors that predict changing the type of phosphodiesterase type 5 inhibitor medication among men in the UKBJU Int20079986086317378846
   PubMed Web of Science ®Google Scholar
• MulhallJPMontorsiFEvaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunctionEur Urol200649303716263207
   PubMed Web of Science ®Google Scholar